Abstract 563P
Background
Around 1.9 million new cancer cases and around 930,000 deaths were attributed to colorectal cancer (CRC) worldwide in 2020. The European Union recommends population-based CRC screening. Reported long‘term results from various CRC screening programs are quite controversial as some of them report no survival gains. In June 2009 the CRC screening program was initiated in Lithuania. The aim of the study is to report the impact of CRC screening program on long-term mortality.
Methods
The anonymous data of the population aged 50-74 from the years 2013 to 2019, who participated in the CRC screening program were extracted from the statistical database of the National Health Insurance Fund, which provided both, the participation in different services of screening indicated by specific codes, and the mortality and survival marked in the database. For statistical analysis we divided patients in three groups: Negative fecal immunochemical test (FIT); positive FIT and screening colonoscopy performed; positive FIT and screening colonoscopy was not performed. The statistical analysis was performed using the R statistical software package v4.2.2.
Results
From the year 2013 to 2019 a total of 1,521551 people participated in the screening program. During the observation period 66920 (4.4%) patients died. The highest mortality was seen in patients that were diagnosed with cancer (19%). High mortality was seen in patients that did not proceed with further colonoscopy after a positive FIT. These patients had a significantly higher mortality rate: Negative FIT (4.2%) vs. Positive FIT + colonoscopy (4.9%) vs. Positive FIT - colonoscopy (8.6%); p<0.001. A univariate logistic regression analysis revealed that positive FIT + colonoscopy (OR 1.19 95% CI 1.15-1.24; p<0.001) and positive FIT - colonoscopy (OR 2.18 95% CI 2.12-2.24; p<0.001) groups had significantly increased mortality risks when compared to the negative FIT group.
Conclusions
Fully completed screening after a positive FIT result is associated with significantly reduced mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10